Video
Dr. Schmoll on the Toxicity of the CHARTA Study in CRC
Author(s):
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).
According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.
Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
